A randomized, double-blind, placebo-controlled clinical study on the intervention of Xuanbi Antong decoction on the syndrome of phlegm-stasis-heat interjunction in critical coronary artery disease.

Study on optimization of key technology and program of whole-course prevention and control of coronary heart disease based on core pathogenesis of phlegm-stasis deficiency——A randomized, double-blind, placebo-controlled clinical study on the intervention of Xuanbi Antong decoction on the syndrome of phlegm-stasis-heat interjunction in critical coronary artery disease.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400083668

Enrollment

Unknown

Registered

2024-04-30

Start date

2024-05-30

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease, CHD

Interventions

Experimental group:Xuanbi Antong prescription granula

Control group:Xuanbi Antong prescription placebo

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Between 30 and 75 years of age, male or female; 2. On the basis of conforming to the diagnosis of coronary atherosclerotic heart disease, the stenosis degree of the target vessel diameter measured by coronary angiography or coronary CTA was 50%-70%; 3. TCM syndrome is broken into phlegm stasis heat interjunction syndrome; 4. Voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Chest pain not caused by coronary heart disease such as severe valvular heart disease, cervical spondylosis, gastroesophageal reflux, and severe neurosis; 2. Coronary artery vessel diameter < 2.0mm, severe twisting disease, left main artery disease, bifurcation disease, severe stenosis affecting blood flow; 3. Renal insufficiency, severe liver dysfunction, abnormal thyroid function; 4. The patient has undergone revascularization including percutaneous coronary intervention or coronary artery bypass grafting; 5. Participants who have participated in or are participating in other clinical trials within the last 1 month.

Design outcomes

Primary

Measure	Time frame
Degree of coronary stenosis;	—

Secondary

Measure	Time frame
CHD angina symptom score;electrocardiogram;Quantitative evaluation of TCM syndrome effect;Seattle Angina Scale;	—

Countries

China

Contacts

Public ContactWang Jie

Guang’anmen Hospital CACMS

wangjie0103@126.com+86 136 0124 0162

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026